Table 3.
INTERAF Patient Characteristics by Participating Registry
| Patient Characteristics | United States NCDR PINNACLE AF Registry | European Society of Cardiology EURObservational Research Program (EORP) AF General Registry | Chinese AF Registry (CAFR) | Brazil PINNACLE AF Registry | Japanese Fushimi AF Registry | Japanese KiCS AF Registry | Balkan‐AF Registry | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N=969 502 | N=3119 | N=17 467 | N=26 | N=4426 | N=1284 | N=2712 | ||||||||
| Number | Percentage | Number | Percentage | Number | Percentage | Number | Percentage | Number | Percentage | Number | Percentage | Number | Percentage | |
| Demographics | ||||||||||||||
| Age, y | ||||||||||||||
| <65 | 240 778 | 24.8 | 1029 | 33.0 | 8678 | 49.7 | 6 | 23.7 | 779 | 17.6 | 539 | 42.0 | 883 | 32.6 |
| 65 to 74 | 313 479 | 32.3 | 1039 | 33.3 | 5077 | 29.1 | 10 | 38.5 | 1337 | 30.2 | 426 | 33.2 | 882 | 32.5 |
| >75 | 502 917 | 51.9 | 1051 | 33.7 | 3712 | 21.3 | 10 | 38.5 | 2310 | 52.2 | 318 | 24.8 | 947 | 34.9 |
| Male | 547 100 | 56.4 | 1859 | 59.6 | 10 716 | 61.4 | 15 | 57.7 | 2607 | 58.9 | 926 | 72.1 | 1485 | 55.5 |
| Race/ethnicity | ||||||||||||||
| White | 657 162 | 67.8 | NA | 0 | 0.0 | 18 | 69.2 | 0 | 0.0 | 0 | 0.0 | 2494 | 92.0 | |
| Black/African | 32 091 | 3.3 | NA | 0 | 0.0 | 3 | 11.5 | 0 | 0.0 | 0 | 0.0 | 218 | 8.0 | |
| American Indian/Alaska Native | 4591 | 0.5 | NA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | NA | ||
| Asian | 8135 | 0.8 | NA | 17 467 | 100.0 | 0 | 0.0 | 4426 | 100.0 | 1284 | 100.0 | NA | ||
| Native Hawaiian/Pacific Islander | 2055 | 0.2 | NA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | NA | ||
| Hispanic/Latino ethnicity | 22 774 | 2.4 | NA | 0 | 0.0 | 5 | 19.2 | 0 | 0.0 | 0 | 0.0 | NA | ||
| South Asian (India/Pakistan/Bangladesh) | NA | NA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | NA | |||
| AF characteristics | ||||||||||||||
| AF type | ||||||||||||||
| Nonvalvular | 961 593 | 99.2 | 1138 | 36.5 | 5766 | 96.4 | 18 | 69.2 | 4218 | 95.3 | 1278 | 99.5 | 2712 | 100.0 |
| Valvular | 7909 | 0.8 | 1981 | 63.5 | 216 | 3.6 | 5 | 19.2 | 208 | 4.7 | 4 | 0.3 | 0 | 0.0 |
| AF duration | ||||||||||||||
| First detected | 47 383 | 4.89 | 945 | 30.3 | 1270 | 7.3 | 1 | 3.8 | NA | 68 | 5.3 | 632 | 23.3 | |
| Paroxysmal | 246 202 | 25.4 | 827 | 26.5 | 9768 | 56.3 | 6 | 23.1 | 1859 | 42.0 | 663 | 51.6 | 556 | 20.5 |
| Persistent | 48 084 | 5.0 | 811 | 26.0 | 6302 | 36.3 | 1 | 3.8 | 420 | 9.5 | 354 | 27.6 | 383 | 14.1 |
| Permanent | NA | 540 | 17.3 | NA | 14 | 53.8 | 2147 | 48.5 | 186 | 14.5 | 1088 | 40.1 | ||
| Unknown | 627 833 | 64.8 | NA | NA | 4 | 15.4 | NA | 13 | 1.0 | 53 | 2.0 | |||
| AF treatment | ||||||||||||||
| Rhythm control | ||||||||||||||
| Antiarrhythmic drug | 366 832 | 37.8 | 1123 | 36.0 | 5854 | 41.3 | 4 | 15.4 | 854 | 19.3 | 728a | 56.7 | 889 | 32.8 |
| Ablation | 40 912 | 4.2 | 237 | 7.6 | 7162 | 41.6 | 0 | 0.0 | 266 | 6.0 | 95 | 3.5 | ||
| Rate control | 849 645 | 87.6 | 1213 | 38.9 | 8202 | 7.8 | 10 | 38.5 | 1987 | 44.9 | 556 | 43.3 | 1622 | 59.8 |
| Stroke risk and prevention | ||||||||||||||
| CHADS2 score, median (IQR) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (2.0–3.0) | 3.0 (2.0–3.0) | 2.0 (1.0–3.0) | 1.0 (0.0–2.0) | 2.0 (1.0–3.0) | |||||||
| CHA2DS2‐VASc score, median (IQR) | 4.0 (3.5–4.5) | 3.0 (2.0–4.0) | 4.0 (2.0–3.0) | 3.0 (2.0–3.0) | 3.0 (2.0–5.0) | 3.0 (2.0–4.0) | 3.0 (2.0–5.0) | |||||||
| OAC among those with either CHADSs or CHA2S2‐VASc score >1 | ||||||||||||||
| Warfarin | 398 816 | 41.1 | 2233 | 71.6 | 5979 | 54.5 | 5 | 19.2 | 1859 | 43.8 | 220 | 17.1 | 461 | 20.1 |
| Acenocoumarol | NA | NA | NA | NA | NA | NA | 964 | 42.0 | ||||||
| Phenprocoumon | NA | NA | NA | 0 | 0.0 | NA | NA | 1 | 0.0 | |||||
| Dabigatran | 81 556 | 8.4 | 212 | 6.8 | 200 | 93.0 | 6 | 23.1 | 152 | 3.6 | 161 | 12.5 | 142 | 6.2 |
| Rivaroxaban | 111 653 | 11.5 | 50 | 1.6 | 6 | 2.8 | 5 | 19.2 | 137 | 3.2 | 266 | 20.7 | 95 | 4.1 |
| Apixaban | 79 742 | 8.2 | 0 | 0.0 | NA | 2 | 7.7 | 130 | 3.1 | 256 | 19.9 | 43 | 1.9 | |
| Edoxaban | 2 349 | 0.24 | NA | NA | 0 | 0.0 | 31 | 0.7 | NA | 0 | 0.0 | |||
| Other | NA | NA | NA | NA | NA | 6 | 0.5 | NA | ||||||
| Other medical conditions | ||||||||||||||
| Coronary artery disease | 479 031 | 49.4 | 1135 | 36.4 | 2647 | 15.2 | 3 | 11.5 | 646 | 14.6 | 101 | 7.9 | 821 | 30.3 |
| Diabetes mellitus | 245 461 | 25.3 | 643 | 20.6 | 3233 | 18.7 | 4 | 15.4 | 1005 | 22.7 | 200 | 15.6 | 668 | 24.6 |
| Hypertension | 770 352 | 79.5 | 2211 | 70.9 | 10 011 | 57.8 | 20 | 76.9 | 2762 | 62.4 | 713 | 55.5 | 2121 | 78.2 |
| Current smoker | 182 998 | 18.9 | 352 | 11.3 | 2075 | 12.0 | 2 | 7.7 | 391 | 8.8 | 217 | 16.9 | 340 | 12.5 |
| Peripheral arterial disease | 102 279 | 10.6 | 349 | 11.2 | 107 | 1.6 | 2 | 7.7 | 186 | 4.2 | 42 | 3.3 | 122 | 4.5 |
| Prior TIA/stroke | 146 132 | 15.1 | 324 | 10.4 | 2509 | 14.5 | 1 | 3.8 | 823 | 18.6 | 103 | 8.0 | 364 | 13.5 |
| Congestive heart failure | 276 642 | 28.5 | 1482 | 47.5 | 1397 | 8.1 | 7 | 26.9 | 1235 | 27.9 | 193 | 15.0 | 1161 | 42.8 |
| Chronic kidney disease | ||||||||||||||
| Stage IIIa (GFR 45–59) | 1117 | 0.1 | NA | 382 | 2.7 | NA | 1226 | 27.7 | 315 | 24.5 | NA | |||
| Stage IIIb (GFR 30–44) | 1222 | 0.1 | NA | 146 | 1.0 | NA | 606 | 13.7 | 169 | 13.2 | NA | |||
| Stage IV (GFR 15–29) | 755 | 0.1 | NA | 60 | 0.4 | NA | 230 | 5.2 | 42 | 3.3 | NA | |||
| Stage V (GFR <15) or HD | 297 | 0.0 | NA | 32 | 0.2 | NA | 124 | 2.8 | 13 | 1.0 | NA | |||
The Brazil PINNACLE registry began enrolling patients in late 2015; The Asia Pacific HRS registry will begin enrolling patients in 2016. AF indicates atrial fibrillation; GFR, glomerular filtration rate; HD, hemodialysis; INTERAF, International Collaborative Partnership for the Study of Atrial Fibrillation; IQR, interquartile range; NA, not available/applicable; NDCR, National Cardiovascular Data Registry; PINNACLE, Practice Innovation and Clinical Excellence; OAC, oral anticoagulant; TIA, transient ischemic attack.
a
Includes both antiarrhythmic drug and AF ablation.